Sunil Parikh, MD, MPH
Professor of Epidemiology (Microbial Diseases) and of Infectious DiseasesCards
Appointments
Additional Titles
Co-Chair Downs Fellowship, Epidemiology of Microbial Diseases
Contact Info
Epidemiology of Microbial Diseases
60 College Street, P.O. Box 208322
New Haven, CA 06520
United States
Appointments
Additional Titles
Co-Chair Downs Fellowship, Epidemiology of Microbial Diseases
Contact Info
Epidemiology of Microbial Diseases
60 College Street, P.O. Box 208322
New Haven, CA 06520
United States
Appointments
Additional Titles
Co-Chair Downs Fellowship, Epidemiology of Microbial Diseases
Contact Info
Epidemiology of Microbial Diseases
60 College Street, P.O. Box 208322
New Haven, CA 06520
United States
About
Titles
Professor of Epidemiology (Microbial Diseases) and of Infectious Diseases
Co-Chair Downs Fellowship, Epidemiology of Microbial Diseases
Biography
Professor Parikh’s research interests focus on translational studies of malaria in sub-Saharan Africa. Dr. Parikh focuses upon several aspects of malaria in sub-Saharan Africa, including studies on optimizing treatment regimens, novel chemoprevention strategies, drug resistance emergence and spread, and parasite dynamics. Current projects include: (1) understanding parasite, drug, and host factors affecting response to artemisinin-based antimalarial therapies using a combination of individual and population-based approaches to inform treatment guidelines (Uganda and Burkina Faso); 2) cluster-randomized trial of endectocides to reduce malaria transmission (Burkina Faso); and 3) characterizing the epidemiology of antimalarial drug resistance and non-falciparum species in sub-Saharan Africa (Cameroon and Burkina Faso), 4) testing of a novel noninvasive diagnostic device for malaria (Cameroon). Dr. Parikh has ongoing projects in several African countries, which utilize observational and cross-sectional designs, as well as prospective clinical trials. Recently, the Parikh lab, in collaboration with colleagues at Colorado State University (Prof Foy), and IRSSINSTech in Burkina Faso (Prof. Dabire and Ouedraogo) were awarded an International Center of Excellence in Malaria Research. Dr. Parikh received his M.D. degree from Johns Hopkins University School of Medicine and completed his medical residency training at the Beth Israel Deaconess Medical Center. After completing his fellowship in Infectious Diseases at the University of California, San Francisco and Masters in Public Health at UC Berkeley he joined the faculty at UCSF. He has been a member of the Department of Epidemiology of Microbial Diseases in the Yale School of Public Health and Section of Infectious Diseases in the Yale School of Medicine since 2012.
Appointments
Epidemiology of Microbial Diseases
ProfessorPrimaryInfectious Diseases
Associate Professor on TermSecondary
Other Departments & Organizations
- African Studies
- Center for Interdisciplinary Research on AIDS
- Epidemiology of Microbial Diseases
- Infectious Diseases
- Internal Medicine
- Parikh Lab
- Yale Institute for Global Health
- Yale School of Public Health
- Yale Ventures
- Yale-UPR Integrated HIV Basic and Clinical Sciences Initiative
- YSPH Global Health Concentration
Education & Training
- MPH
- University of California at Berkeley (2005)
- Fellow
- University of California - San Francisco (2004)
- Resident
- Beth Israel Deaconess Medical Center - Boston (2001)
- MD
- Johns Hopkins University School of Medicine (1998)
Research
Overview
1) Antimalarial therapy/efficacy studies in children and those with HIV/malaria co-infection in Uganda
Major Goal: To assess the pharmacokinetics and pharmacodynamics of artemisinin-combination therapies, toxicity of newer antiretrovirals (dolutegravir), and determinants of artemisinin partial drug resistance in two different settings in Uganda.
2) Use of novel approaches to preventing malaria in Burkina Faso
Major Goal: We are conducting a cluster-randomized trial of a novel chemopreventive approach in Burkina Faso
3) Characterizing the epidemiology of malaria species across three different transmission zones in Burkina Faso through longitudinal human cohorts coupled with spatial mapping and mosquito studies (Burkina Faso ICEMR - "PIVOTAL")
4) Development and diagnostic performance studies of a non-invasive diagnostic device for malaria in Cameroon and Burkina Faso.
Medical Subject Headings (MeSH)
- View Lab Website
Parikh Lab
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Martina Wade
Fangyong Li, MS, MPH
Justin Goodwin
Jean Bosco Ouedraogo
Amy Bei, PhD
Kaicheng Wang, MD, MPH
Publications
2024
Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children
Goodwin J, Kajubi R, Wang K, Li F, Wade M, Orukan F, Huang L, Whalen M, Aweeka F, Mwebaza N, Parikh S. Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children. Nature Communications 2024, 15: 3817. PMID: 38714692, PMCID: PMC11076639, DOI: 10.1038/s41467-024-48210-7.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDay 7 lumefantrine concentrationsArtemether-lumefantrine treatmentRing-stage parasitesEarly post-treatmentEarly post-treatment periodArtemether-lumefantrineArtemisinin resistanceDay regimenMulticlonal infectionsEfficacious therapyFollow-upRandomized trialsPersistent clonesTransmission settingsEffective treatmentPost-treatment periodRegimensAntimalarial studiesStandard diagnosticsStandard 3DaysPost-treatmentChildrenTreatmentTherapy
2023
Tracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study
Ehrlich H, Somé A, Bazié T, Ebou C, Dembélé E, Balma R, Goodwin J, Wade M, Bei A, Ouédraogo J, Foy B, Dabiré R, Parikh S. Tracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study. The Lancet Microbe 2023, 4: e461-e469. PMID: 37086737, PMCID: PMC10365133, DOI: 10.1016/s2666-5247(23)00063-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMosquito blood mealsAntimalarial drug resistanceSurvey 3Blood-fed mosquitoesBlood samplesSurvey 1Survey 2Blood mealDrug resistanceUltrasensitive quantitative PCRHuman blood samplesCross-sectional studyMargin of equivalenceStrong surveillance systemCross-sectional surveySupplementary Materials sectionMarker of clonalityPragmatic thresholdAntimalarial resistanceDrug susceptibilityInfectious diseasesPlasmodium falciparumNational InstituteTolerabilityMaterial sectionRepeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria
Foy B, Some A, Magalhaes T, Gray L, Rao S, Sougue E, Jackson C, Kittelson J, Slater H, Bousema T, Da O, Coulidiaty A, Colt M, Wade M, Richards K, Some A, Dabire R, Parikh S. Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria. JMIR Research Protocols 2023, 12: e41197. PMID: 36939832, PMCID: PMC10132043, DOI: 10.2196/41197.Peer-Reviewed Original ResearchCitationsAltmetricConceptsIvermectin mass drug administrationMass drug administrationINTERNATIONAL REGISTERED REPORT IDENTIFIERMalaria incidenceDrug AdministrationMalaria transmissionIntense seasonal malaria transmissionMalaria controlSecondary safety outcomesParallel-group trialSeasonal malaria transmissionAdverse event monitoringActive case surveillancePrimary outcomeControl IINonpregnant individualsPostintervention changesTrial interventionCare interventionsSafety outcomesCluster RandomizedSubset of individualsCase surveillanceConsecutive daysEntomological assessmentsArtemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi
Nyangulu W, Mungwira R, Divala T, Nampota-Nkomba N, Nyirenda O, Buchwald A, Miller J, Earland D, Adams M, Plowe C, Taylor T, Mallewa J, van Oosterhout J, Parikh S, Laurens M, Laufer M. Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi. Malaria Journal 2023, 22: 32. PMID: 36707795, PMCID: PMC9881508, DOI: 10.1186/s12936-023-04466-w.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsAntiretroviral therapyLumefantrine levelsTreatment failureDrug-drug interactionsACPR ratesMalaria infectionTrimethoprim-sulfamethoxazolePCR correctionTreatment efficacyUndetectable HIV RNA viral loadEfavirenz-based antiretroviral therapyHIV RNA viral loadUncomplicated Plasmodium falciparum malariaHuman immunodeficiency virus (HIV) infectionArtemether-lumefantrine efficacyCohort of PWHEfavirenz-based regimensImmunodeficiency virus infectionRNA viral loadPlasmodium falciparum malariaMalaria treatment failurePopulation of adultsRandom-effects modelTherapeutic efficacy monitoringLumefantrine exposure
2022
Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda
Kay K, Goodwin J, Ehrlich H, Ou J, Freeman T, Wang K, Li F, Wade M, French J, Huang L, Aweeka F, Mwebaza N, Kajubi R, Riggs M, Ruiz‐Garcia A, Parikh S. Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. Clinical Pharmacology & Therapeutics 2022, 113: 660-669. PMID: 36260349, PMCID: PMC9981240, DOI: 10.1002/cpt.2768.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsLopinavir-ritonavirLumefantrine concentrationsSensitive parasitesRecurrence riskPopulation PK/PD modelArtemether-lumefantrine treatmentTrimethoprim-sulfamethoxazole prophylaxisPK/PD modelPopulation PK modelFirst-order absorptionHigh transmission regionsAntiretroviral regimensLumefantrine exposureLumefantrine susceptibilityPfcrt K76Pfmdr1 N86Suboptimal dosingArtemether-lumefantrineTwo-compartment modelHIV statusRecurrent infectionsCombination therapyDrug exposurePrimary treatmentArtemisinin resistanceClinical characteristics of Plasmodium falciparum infection among symptomatic patients presenting to a major urban military hospital in Cameroon
Hodson DZ, Mbarga Etoundi Y, Mbatou Nghokeng N, Mohamadou Poulibe R, Magne Djoko S, Goodwin J, Cheteug Nguesta G, Nganso T, Armstrong JN, Andrews JJ, Zhang E, Wade M, Eboumbou Moukoko CE, Boum Y, Parikh S. Clinical characteristics of Plasmodium falciparum infection among symptomatic patients presenting to a major urban military hospital in Cameroon. Malaria Journal 2022, 21: 298. PMID: 36273147, PMCID: PMC9588226, DOI: 10.1186/s12936-022-04315-2.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsP. falciparum infectionPopulation attributable risk percentFalciparum infectionPlasmodium falciparum infectionYears of ageClinical characteristicsUrban hospitalMilitary HospitalAttributable risk percentHigher positivity rateLikelihood ratioRapid diagnostic testsMajor urban hospitalRural African settingConclusionsThe prevalenceHigh feverSymptomatic patientsHemoglobin levelsAnemia prevalenceSevere anemiaEmergency departmentVenous samplesClinical surveyPositivity rateWHO definitionThe Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial
Whalen ME, Kajubi R, Goodwin J, Orukan F, Colt M, Huang L, Richards K, Wang K, Li F, Mwebaza N, Aweeka FT, Parikh S. The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial. Clinical Infectious Diseases 2022, 76: 443-452. PMID: 36130191, PMCID: PMC9907485, DOI: 10.1093/cid/ciac783.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsArtemether-lumefantrineReinfection riskArtemisinin-based combination therapyDay 7 levelsOverall drug exposureHigh transmission settingsYoung childrenAntimalarial exposureUncomplicated malariaExtended regimenRecurrent parasitemiaControlled TrialsPrimary outcomeCombination therapyKaplan-MeierDrug exposureTotal episodesUgandan childrenArtemisinin resistanceLumefantrine concentrationsPharmacodynamic studiesHigh riskPharmacokinetic parametersRecurrence riskDay 7Genetic Variants of Glucose-6-Phosphate Dehydrogenase and Their Associated Enzyme Activity: A Systematic Review and Meta-Analysis
Pfeffer DA, Satyagraha AW, Sadhewa A, Alam MS, Bancone G, Boum Y, Brito M, Cui L, Deng Z, Domingo GJ, He Y, Khan WA, Kibria MG, Lacerda M, Menard D, Monteiro W, Pal S, Parikh S, Roca-Feltrer A, Roh M, Sirdah MM, Wang D, Huang Q, Howes RE, Price RN, Ley B. Genetic Variants of Glucose-6-Phosphate Dehydrogenase and Their Associated Enzyme Activity: A Systematic Review and Meta-Analysis. Pathogens 2022, 11: 1045. PMID: 36145477, PMCID: PMC9502867, DOI: 10.3390/pathogens11091045.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSystematic reviewMedian activityDrug-induced haemolysisG6PD activityIndividual patient dataGenetic variantsGlucose-6-phosphate dehydrogenase enzyme activityStudy-specific definitionsMeta-AnalysisG6PD genotypeNormal activityPatient dataRelevant genetic variantsDifferent genetic variantsEnzymatic deficiencyGlucose-6-phosphate dehydrogenaseEnzyme activityVanua LavaAssociated enzyme activitiesG6PD mutationsViangchanDehydrogenase enzyme activityCurrent classificationTowards rainbow portable Cytophone with laser diodes for global disease diagnostics.
Jawad HJ, Yadem AC, Menyaev YA, Sarimollaoglu M, Armstrong JN, Watanabe F, Biris AS, Stumhofer JS, Nedosekin D, Suen JY, Parikh S, Zharov VP. Towards rainbow portable Cytophone with laser diodes for global disease diagnostics. Scientific Reports 2022, 12: 8671. PMID: 35606373, PMCID: PMC9126638, DOI: 10.1038/s41598-022-11452-w.Peer-Reviewed Original ResearchRepeatability and reproducibility of a handheld quantitative G6PD diagnostic
Ley B, Satyagraha A, Kibria MG, Armstrong J, Bancone G, Bei AK, Bizilj G, Brito M, Ding XC, Domingo GJ, von Fricken ME, Gornsawun G, Lam B, Menard D, Monteiro W, Ongarello S, Pal S, Panggalo LV, Parikh S, Pfeffer DA, Price RN, da Silva Orfano A, Wade M, Wojnarski M, Worachet K, Yar A, Alam MS, Howes RE. Repeatability and reproducibility of a handheld quantitative G6PD diagnostic. PLOS Neglected Tropical Diseases 2022, 16: e0010174. PMID: 35176015, PMCID: PMC8853557, DOI: 10.1371/journal.pntd.0010174.Peer-Reviewed Original ResearchCitationsAltmetric
Academic Achievements & Community Involvement
activity COVID-19 in Connecticut Long-term Care Facilities
ResearchDetails04/01/2020 - PresentNew Haven, CT, United StatesAbstract/SynopsisContract with DPH to assist in surveillance and infection prevention and control of COVID-19 in long-term care facilities
activity Integration of HIV, TB, and malaria
ResearchDetails04/01/2019 - PresentPort-au-Prince, Ouest Department, Haitiactivity Malaria research in Cameroon
ResearchDetails09/01/2017 - PresentYaounde, Centre, CameroonCollaborators- Yap Boum IIMSF Epicentre
Abstract/SynopsisNovel non-invasive diagnosis of malaria
honor Hecht-Albert Pilot Innovation Award for Junior Faculty
Yale University AwardGlobal Health Leadership InstituteDetails05/02/2016United Statesactivity Alliance for Stroke Awareness and Prevention Project
VolunteerActivityDetails01/01/2011 - PresentNew Delhi, NCT, India; Kampala, Central Region, UgandaAbstract/SynopsisBoard Member, Non-profit working in Uganda and India on projects related to stroke prevention, such as hypertension screening.
Teaching & Mentoring
Teaching
Didactic EMD 567: Tackling the Big Three: Malaria, TB, and HIV in Resource-Limited Settings
LecturerLecture SettingDetails9/1/2014 - PresentForGraduate30 Average Instructional Hours Per YearMalaria, tuberculosis, and HIV account for more than five million deaths worldwide each year. This course provides a deep foundation for understanding these pathogens and explores the public health issues that surround these infectious diseases in resource-limited settings. Emphasis is placed on issues in Africa, but contrasts for each disease are provided in the broader developing world. The course is divided into three sections, each focusing in depth on the individual infectious disease as well as discussions of interactions among the three diseases. The sections consist of three to four lectures each on the biology, individual consequences, and community/public health impact of each infectious disease. Discussion of ongoing, field-based research projects involving the diseases is led by relevant faculty (research into practice). The course culminates with a critical discussion of major public health programmatic efforts to tackle these diseases, such as those of PEPFAR, the Bill & Melinda Gates Foundation, the Global Fund, and the Stop TB Partnership.
News & Links
News
Get In Touch
Contacts
Epidemiology of Microbial Diseases
60 College Street, P.O. Box 208322
New Haven, CA 06520
United States
Administrative Support
Locations
60 College Street
Lab
Ste 7th floor
New Haven, CT 06510
60 College Street
Academic Office
Ste 724
New Haven, CT 06510